Novel diagnostic and prognostic biomarkers for different cancer types CanIso.netA new database to assess the impact of cancer-specific Most Dominant Transcripts (cMDT) using an isoform-specific interaction network. Alternative RNA splicing is a regulatory cellular mechanism to create multiple mRNA molecules from the same gene…
Synthetic glycolipids for the treatment of rare diseases GPI-Anchored Proteins Biosynthesis Rescue We established a synthetic strategy for the chemical synthesis of glycosylphosphatidylinositols having unsaturated lipids. This strategy was used in a project with the group of Prof. Taroh Kinoshita from Osaka University and the Max Planck…
Novel tool for process development Together with members of the association Miniplant 4.0 the group of Prof. Dr. A. Zogg has developed a novel Scale-Down-Reactor. The new prototype reactor is installed within the process technology center at the FHWN-HLS. The hart of the novel Scale-Down-Reactor is…
Novel tool for process development In cooperation with the company Fluitec AG as well as Schärer und Schläpfer AG the group of Prof. Dr. A. Zogg is currently developing a novel, model based safety concept for…
In vitro models for liver disease suffer from the lack of well-established and sensitive biomarkers of cellular damage. MicroRNAs (miRNAs; small noncoding RNAs) represent potential biomarkers for the detection of drug-induced liver injury in vivo and in vitro. Altered physiological state caused by disease or tissue damage results in altered release of exosomal- or protein-bound miRNAs, detectable in body fluids and cell culture media...
Integrated cascades of processes for the extraction and valorisation of proteins and bioactive molecules from legumes, fungi and coffee agro-industrial side streams. Under this title, PROLIFIC applies new, innovative, technological and industrial solutions to transform agro-industrial residues into higher value products....
In FuturEnzyme, a multi-disciplinary and multi-actor consortium of 16 leading academic and industrial partners will develop technologies of the FUTURe for low-cost ENZYMEs for environment-friendly products. The high-tech enzyme development platform will use big biodata mining of both public and internal databases and bio-resources, and disruptive machine learning, activity-based bioprospecting, protein engineering, nano-biotechnology, upscale fermentation, and downstream processing systems...